Xiaomei Gao

12 Urumqi Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Correction: Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44 + cancer stem cells to 5 azacytidine in hepatocellular carcinoma.

Correction: Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44 + cancer stem cells to 5 azacytidine in hepatocellular carcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 14, 2023

Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.

Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.

Journal: Signal transduction and targeted therapy

Published: August 16, 2020

STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.

STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.

Journal: Cancer science

Published: September 10, 2019

Genome-Wide Association Study Identifies a Genetic Prediction Model for Postoperative Survival in Patients with Hepatocellular Carcinoma.

Genome-Wide Association Study Identifies a Genetic Prediction Model for Postoperative Survival in Patients with Hepatocellular Carcinoma.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: April 05, 2019

Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression.

Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 25, 2018

Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma.

Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma.

Journal: International journal of cancer

Published: July 21, 2018

Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.

Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 13, 2018

The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma.

The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 03, 2018

Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway.

Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway.

Journal: Oncology letters

Published: January 05, 2017

Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin.

Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin.

Journal: Oncotarget

Published: July 09, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026